Incyte Corp - Rasio nilai perusahaan marang dodolan INCY

Simbol resmi perusahaan incyte.com (INCY)

High R&D expenditures and patent protection create significant barriers to entry in oncotherapy. The change in the enterprise value-to-revenue multiple clearly illustrates the financial stability of Incyte Corporation (INCY), where the 3294.25 mark records this metric. Experienced management seeks to diversify the portfolio beyond Jakafi, relying on a stable staff of leading scientists retained through lucrative stock option programs.

Incyte Pharma (INCY): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Incyte Corp. - rincian analitis lan metrik utama (INCY)

Pambiji fundamental perusahaan:INCY, incyte.com
Produk sing diprodhuksi Incyte Corp

This indicator reflects the market value of the business, including net debt, relative to the volume of generated sales. By analyzing the current enterprise value-to-revenue ratio, an investor assesses the efficiency of asset monetization regardless of leverage. For Incyte Corporation (INCY), the stability of this ratio is critical, as it mitigates the risks of dependence on a single drug, Jakafi, and the volatility of clinical trials.

Analisis pesaing

Rasio nilai perusahaan marang dodolan HUTCHMED (HCM)|NUVB: Multiplikator EV/Sales|Rasio nilai perusahaan marang dodolan Day One Bio DAWN|Nilai perusahaan marang pendapatan MNPR|Multiplikator nilai perusahaan marang pendapatan Inhibrx Biosciences INBX|Nilai perusahaan marang pendapatan IMAB (I-Mab Biopharma Co., Ltd.)|FENC (Fennec Pharmaceuticals Inc.) - Nilai bisnis marang pendapatan|Heron Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan NVCT (Nuvectis Pharma)|Coherus BioSciences, Inc. - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CRBP (Corbus Pharma)|CRDF: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan beyondspringpharma.com (BYSI)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales